ELISA: 1: 20000approx. 1: 40000. WB: 1: 500approx. 1: 1000. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
DO NOT FREEZE!
Lagerung
4 °C
Informationen zur Lagerung
Store the antibody undiluted at 2-8 °C.
Target
HMG20B
(High Mobility Group 20B (HMG20B))
Andere Bezeichnung
SMARCE1-Related Protein
Hintergrund
The breast cancer susceptibility gene (BRCA1) localizes to chromosome 17q. Mutations within this gene account for approximately 45 % of families with high incidence of breast cancer and at least 80 % of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2, located on chromosome 13q12-13, also confers a high incidence of breast cancer, but unlike BRCA1, BRCA2 does not confer a substantially elevated risk of ovarian cancer. The BRCA2-Associated Factor 35 (BRAF35) protein forms a 20 kDa complex with BRCA2, which associates with condensed chromatin during histone H3 phosphorylation. BRAF35 expression levels are highest in proliferating tissues and parallel BRCA2 expression patterns. The structure of BRAF35 includes a kinesinlike coiled coil domain and a nonspecific DNA binding HMG domain. The chromatin localization of BRAF35 and antibody microinjection studies indicate a role for the BRAF35/BRCA2 complex in cell cycle regulation.Synonyms: BRAF35, BRCA2-associated factor 35, HMG box-containing protein 20B, HMG domain-containing protein 2, HMG domain-containing protein HMGX2, HMG20B, HMGX2, HMGXB2, SMARCE1R, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related, Sox-like transcriptional factor, Structural DNA-binding protein BRAF35